FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII ...
more